Lilly's Basal Insulin Peglispro Shows Novel Mechanism of Action Data presented at the 74th American Diabetes Association Scientific Sessions® expand body of evidence for the mechanism of action of basal insulin peglispro in healthy human subjects
SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data regarding the mechanism of action of basal insulin peglispro (BIL). When BIL and insulin glargine were each administered to achieve complete suppression of glucose production, which principally comes from the liver, BIL showed less activity in peripheral tissues, such as muscle and fat, than insulin glargine.1 The data will be presented at the 74th American Diabetes Association Scientific Sessions®.
"What's exciting about this particular study is that it provides further evidence that basal insulin peglispro works in a fundamentally different way in the body compared to insulin glargine," said David Kendall, M.D., vice president, Medical Affairs, Lilly Diabetes. "We saw a similar effect in earlier animal studies comparing BIL to an infusion of human insulin. These studies taken together support our hypothesis that BIL works in a manner more similar to the body's own insulin when compared to other exogenous insulins."
In this study, researchers measured both glucose disposal rate (GDR) and endogenous glucose production (EGP) rate to characterize peripheral vs. hepatic insulin action.1
BIL, which was discovered and developed in Lilly Research Laboratories, is currently in Phase III clinical trials, and is among several diabetes molecules in Lilly's late-stage pipeline.
About the Study
In this single-center crossover study, 8 male subjects (23 to 27 years) had 8-hour euglycemic clamps performed with continuous intravenous infusions of BIL and insulin glargine. A tracer was infused to assess rates of EGP and glucose disposal. Five doses of BIL and 2 doses of insulin glargine were investigated.
Approximately 24.4 million Americans and an estimated 382 million people worldwide have type 1 and type 2 diabetes. Type 2 diabetes is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases. Diabetes is a chronic disease that occurs when the body either does not properly produce, or use, the hormone insulin.2
About Basal Insulin Peglispro
Basal insulin peglispro, which was discovered and developed in Lilly Research Laboratories, is currently in Phase III clinical trials and is among several diabetes molecules in the Lilly late-stage pipeline. BIL is an investigational basal insulin being studied as a once-daily treatment for type 1 and type 2 diabetes.
About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a broad and growing product portfolio and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. For more information, visit www.lillydiabetes.com.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels.
This press release contains forward-looking statements about an investigational compound, basal insulin peglispro, which is currently in development for the treatment of diabetes. It reflects Lilly's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. There is no guarantee that future study results and patient experience will be consistent with study findings to date or that basal insulin peglispro will receive required regulatory approvals or prove to be commercially successful. For further discussion of these and other risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.
- Henry, R, Mudaliar, S, et al. Basal Insulin Peglispro Demonstrates Hepatic versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects. Poster 886-P. Presented at 74th American Diabetes Association (ADA) Scientific Sessions; June 13-17, 2014; San Francisco, CA.
- International Diabetes Federation. Diabetes Atlas, 6th Edition: Fact Sheet. 2013.
Refer to: Molly McCully, +1-317-478-5423, firstname.lastname@example.org
SOURCE Eli Lilly and Company